Page 109 - Read Online

Gurule et al. Cancer Drug Resist 2018;1:118-25 I http://dx.doi.org/10.20517/cdr.2018.12 Page 125

(anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR MT)
advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32:8022.
43. Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell
lung cancer. JAMA Oncol 2018;4:1112-5.
44. Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G
Jr. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase
translocation - positive advanced non-small cell lung cancer (CheckMate 370). J Thorac Oncol 2018;13:682-8.
45. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, Marinos G, Lloyd AR. Expression of the chemokine IP-10
(CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc
Biol 2003;74:360-9.
46. Pechkovsky DV, Goldmann T, Ludwig C, Prasse A, Vollmer E, Müller-Quernheim J, Zissel G. CCR2 and CXCR3 agonistic chemokines
are differently expressed and regulated in human alveolar epithelial cells type II. Respir Res 2005;6:75.
47. Harada C, Kawaguchi T, Ogata-Suetsugu S, Yamada M, Hamada N, Maeyama T, Souzaki R, Tajiri T, Taguchi T, Kuwano K, Nakanishi
Y. EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. Am J Respir Crit Care Med
2011;183:743-51.
48. Mikumo H, Yanagihara T, Hamada N, Harada E, Ogata-Suetsugu S, Ikeda-Harada C, Arimura-Omori M, Suzuki K, Yokoyama T,
Nakanishi Y. Neutrophil elastase inhibitor sivelestat ameliorates gefitinib-naphthalene-induced acute pneumonitis in mice. Biochem
Biophys Res Commun 2017;486:205-9.